| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥2149.9B | ¥2169.9B | -0.9% |
| Operating Income | ¥46.2B | ¥57.8B | -20.0% |
| Ordinary Income | ¥54.4B | ¥64.8B | -16.0% |
| Net Income | ¥34.6B | ¥39.9B | -13.1% |
| ROE | 3.0% | 3.5% | - |
FY2026 Q3 results showed Kawachi Pharmacy facing revenue and profitability pressures. Revenue reached 214.9B yen (YoY -0.9%), Operating Income 4.6B yen (YoY -20.0%), Ordinary Income 5.4B yen (YoY -16.0%), and Net Income 3.5B yen (YoY -13.1%). Operating margin declined 0.51 percentage points to 2.15% from prior year's 2.66%, driven by gross margin compression of 0.19 percentage points to 22.9% and SG&A ratio expansion of 0.33 percentage points to 20.7%. The company maintains solid financial health with cash position of 42.4B yen against modest long-term debt of 9.3B yen, though inventory buildup of 36.5B yen (up 6.9% YoY) signals potential efficiency challenges. Full-year guidance projects revenue of 287.0B yen (-0.3% YoY) and operating income of 6.0B yen (-19.6% YoY), reflecting continued cost pressures while maintaining dividend commitment of 100 yen per share.
[Profitability] ROE of 3.0% remains below industry standards, decomposing to net margin 1.6% multiplied by asset turnover 1.048 and financial leverage 1.77. Operating margin contracted to 2.15% from 2.66% prior year, with gross margin declining 0.19 percentage points to 22.9% and SG&A ratio rising 0.33 percentage points to 20.7%. Net margin decreased to 1.61% from 1.84% YoY. EBIT margin stands at 2.1%, indicating limited operating leverage. [Cash Quality] Cash and deposits of 42.4B yen increased 15.7% YoY, providing short-term debt coverage of 0.77x against current portion of long-term debt of 5.5B yen. Interest coverage ratio remains strong at 85.6x, demonstrating robust debt servicing capacity despite modest interest expense increase to 0.5B yen from 0.3B yen. [Investment Efficiency] Asset turnover maintained at 1.05x as total assets grew to 205.1B yen. Inventory increased 6.9% to 36.5B yen while revenue declined 0.9%, suggesting inventory turnover deceleration. ROIC calculated at approximately 3.6% reflects modest capital productivity. [Financial Health] Equity ratio of 56.6% improved from 57.3% as total equity reached 116.2B yen. Current ratio of 146.3% falls marginally below 150% threshold, while quick ratio of 90.6% indicates inventory-dependent liquidity structure. Debt-to-equity ratio remains conservative at 0.08x with total interest-bearing debt of 9.3B yen. Accounts payable increased 10.7% to 45.7B yen, reflecting working capital optimization through extended payment terms.
Cash and deposits increased 5.8B yen YoY to 42.4B yen, demonstrating ongoing cash accumulation despite profitability pressures. Operating profit contribution supported core liquidity, while working capital dynamics showed inventory buildup of 2.4B yen creating cash usage headwinds partially offset by accounts payable expansion of 4.4B yen, generating net working capital benefit of approximately 2.0B yen. The 10.7% growth in accounts payable against 6.9% inventory increase reflects effective supplier credit utilization to finance working capital needs. Long-term debt decreased 1.4B yen through scheduled repayments, reducing financial leverage while maintaining comfortable interest coverage. Cash coverage of current liabilities stands at 0.65x, though combined with highly liquid working capital positions, near-term liquidity risk remains contained. The accrued bonus provision increased 0.8B yen (up 68.3%), indicating personnel cost escalation requiring cash outlay in subsequent periods. Asset retirement obligations in current liabilities decreased 0.3B yen, suggesting completion of scheduled store closures. Overall cash position improvement of 15.7% YoY amid modest revenue decline demonstrates disciplined capital management and balance sheet resilience.
Ordinary income of 5.4B yen versus operating income of 4.6B yen shows non-operating net contribution of approximately 0.8B yen, comprising primarily interest and dividend income alongside other financial income. Non-operating income represents 0.5% of revenue, consisting of interest and dividend income of 0.9B yen, equity method investment gains, and other recurring financial items, partially offset by interest expense of 0.5B yen which doubled from 0.3B yen prior year as interest rates normalized. The non-operating contribution remains modest and stable relative to core operations. Special items included store closure losses of 0.4B yen and impairment losses of 0.7B yen, totaling 1.1B yen in non-recurring charges representing routine asset portfolio optimization rather than extraordinary events. These charges represent 0.05% of revenue and reflect ongoing store rationalization discipline. The composition shows earnings primarily driven by core pharmacy operations with limited dependency on non-operating sources. Accruals assessment indicates inventory buildup outpacing sales growth while payables expansion suggests some working capital benefit, though the inventory-sales mismatch warrants attention for potential markdown or obsolescence risk. The net profit margin compression from 1.84% to 1.61% reflects genuine operational pressure rather than accounting distortions, with gross margin decline and SG&A deleverage as primary drivers.
Gross margin compression of 0.19 percentage points to 22.9% driven by intensified competitive pricing, product mix deterioration, and increased markdown rates poses ongoing profitability risk requiring pricing optimization and private brand expansion to offset. SG&A ratio expansion of 0.33 percentage points to 20.7% despite revenue decline creates negative operating leverage, with structural cost increases in wages (bonus provision up 68.3%), utilities, and logistics difficult to reverse quickly. Inventory accumulation of 6.9% against revenue decline of 0.9% signals turnover deceleration risk, with carrying value of 36.5B yen representing 17.0% of total assets vulnerable to markdown or obsolescence if demand weakens further. Quick ratio of 90.6% below 100% threshold indicates inventory-dependent liquidity structure, creating vulnerability to working capital stress if inventory monetization slows or payable terms tighten. Drugstore industry competitive intensity with price deflationary pressures threatens sustained margin recovery, requiring differentiation through healthcare services and digital engagement to maintain customer traffic.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: Operating margin 2.2% compares to industry median 4.0% (IQR: 1.8%-11.6%), positioning in lower quartile and indicating room for improvement through gross margin enhancement and cost efficiency. Net profit margin 1.6% approximates industry median 1.7% (IQR: 0.4%-7.9%), suggesting relative alignment on bottom-line efficiency despite operating underperformance. ROE 3.0% tracks industry median 3.2% (IQR: 0.8%-8.1%), reflecting sector-wide capital efficiency challenges rather than company-specific weakness.
Financial Health: Equity ratio 56.6% aligns with industry median 55.2% (IQR: 36.8%-62.6%), demonstrating solid capitalization consistent with peer group. Current ratio 146.3% falls below industry median 212% (IQR: 142%-293%), placing the company in lower half of liquidity distribution and highlighting inventory-dependent working capital structure relative to peers. Net debt position remains negative (net cash) comparing favorably to industry median -0.45x EBITDA (IQR: -4.39x to 1.17x), confirming strong balance sheet positioning.
Efficiency: Revenue growth of -0.9% significantly trails industry median 7.9% (IQR: 2.5%-12.4%), placing the company in contraction mode while sector demonstrates expansion, requiring strategic focus on store productivity and market share capture. ROA of 1.7% exceeds industry median 1.2% (IQR: 0.3%-4.9%), suggesting relatively efficient asset utilization despite revenue headwinds.
(Industry: Retail sector, N=11 companies, Comparison: 2025-Q3 period, Source: Proprietary analysis)
Margin recovery trajectory represents critical near-term focus as operating margin of 2.2% trails industry median 4.0% by 1.8 percentage points, with gross margin improvement through product mix optimization and private brand expansion alongside SG&A efficiency gains through labor productivity and digital process automation constituting primary value drivers. Inventory management discipline emerges as key operational priority given 6.9% buildup against declining sales creating 36.5B yen exposure, requiring accelerated turnover through demand forecasting accuracy, SKU rationalization, and markdown optimization to unlock working capital and reduce obsolescence risk. Balance sheet strength provides strategic flexibility with net cash position, 56.6% equity ratio, and 85.6x interest coverage enabling continued dividend commitment of 100 yen per share (approximately 60% payout ratio on full-year EPS guidance of 165.66 yen) while preserving capacity for growth investments or store portfolio optimization to drive sustainable ROIC improvement from current 3.6% level.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.